tbuckley/cabot-search huggingface dataset:
Effects of Chronic Cyclophosphamide and Methotrexate Treatment on Skin Allograft Survival in Mice and Rats 2
Authors: Margaret L. Kripke, David Steinmuller, Curtis C. Harris, Paul E. Lofgreen, Ernst J. Eichwald
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Effects of Chronic Cyclophosphamide and Methotrexate Treatment on Skin Allograft Survival in Mice and Rats Get access Margaret L. Kripke, Margaret L. Kripke Search for other works by this author on: Oxford Academic PubMed Google Scholar David Steinmuller, David Steinmuller Search for other works by this author on: Oxford Academic PubMed Google Scholar Curtis C. Harris, Curtis C. Harris Search for other works by this author on: Oxford Academic PubMed Google Scholar Paul E. Lofgreen, Paul E. Lofgreen Search for other works by this author on: Oxford Academic PubMed Google Scholar Ernst J. Eichwald Ernst J. Eichwald Department of Pathology, University of Utah College of Medicine, Salt Lake City, Utah 84112; and Lung Cancer Branch (CCH), Carcinogenesis Program, National Cancer Institute, National Institutes of Health, Public Health Service, U.S. Department of Health, Education, and Welfare, Bethesda, Md. 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 4, October 1973, Pages 1355–1358, https://doi.org/10.1093/jnci/51.4.1355 Published: 01 October 1973 Article history Received: 19 June 1973 Accepted: 27 June 1973 Published: 01 October 1973
What is femoroacetabular impingement?
Authors: R Agricola, H Weinans
Journal: British Journal of Sports Medicine (2015)

Femoroacetabular impingement (FAI) has gained much attention over the past decade. It has been associated with hip and groin pain, decreased hip function and can ultimately lead to osteoarthritis.1 A recent consensus meeting defined FAI as “a clinical entity in which a pathological mechanical process causes hip pain when morphological abnormalities of the acetabulum and/or femur, combined with vigorous hip motion (especially at the extremes), lead to repetitive collisions that damage the soft-tissue structures within the joint itself.”2 However, there is a lack of clarity regarding the definition of morphological abnormalities.

The presence of a cam or pincer deformity is a prerequisite for defining cam-type and pincer-type of FAI. Although an obvious cam deformity is not difficult to recognise, there may be subtle differences between normal and abnormal bony morphology. This is illustrated by a study showing poor correlation between the subjective assessment of the head–neck junction and objective measures.3 Poor reliability of radiologists and orthopaedic surgeons in quantifying morphological abnormalities has also been demonstrated.4 Objective methods to quantify a cam deformity are, therefore, preferable. Several …
증례 : Fluoxetine에 의한 급성 독성 간염
Authors: 곽성재(Seong Jae Kwak), 오흥영(Heung Young Oh), 여미애(Mi Ae Yeo), 박수현(Soo Hyun Park), 김지수(Jee Soo Kim), 이준상(Joon Sang Lee), 이중서(Joong Seo Lee), 김형건(Hyung Gun Kim)
Journal: Clinical and Molecular Hepatology (2000)

Fluoxetine (Prozac ) is a antidepressant that inhibits the reuptake of serotonin in central nervous system, and has lesser adverse effects than the tricyclic antidepressants. The adverse effects of this drug are various, and the most common side effects are headache and nausea. The hepatic injury caused by fluoxetine is reported but very rare and not well known. Literature review has shown only 3 cases of hepatotoxicity from fluoxetine. We regard our case as the first of the hepatotoxicity from fluoxetine in Korea. The patient that we experienced showed normal aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values before fluoxetine administration. 15 days after she took fluoxetine, AST and ALT values were increased and gradually increased as she took fluoxetine daily. We studied about viral hepatitis, metabolic liver disease, and autoimmune liver disease, but the cause of hepatic injury was not established. After the patient stopped to take fluoxetine, AST and ALT values decreased. A liver biopsy showed a moderate infiltration within the portal tracts with lymphocytes and ballooning degeneration of hepatocytes. We concluded fluoxetine-induced acute toxic hepatitis had occured. We must keep in mind that fluoxetine may cause hepatitis without cholestasis and suggest taking liver function tests regularly.(Korean J Hepatol 2000;6:236-240)
Five-Year Mortality and Hospital Costs Associated with Surviving Intensive Care
Authors: Nazir I. Lone, Michael A. Gillies, Catriona Haddow, Richard Dobbie, Kathryn M. Rowan, Sarah H. Wild, Gordon D. Murray, Timothy S. Walsh
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Rationale: Survivors of critical illness experience significant morbidity, but the impact of surviving the intensive care unit (ICU) has not been quantified comprehensively at a population level.Objectives: To identify factors associated with increased hospital resource use and to ascertain whether ICU admission was associated with increased mortality and resource use.Methods: Matched cohort study and pre/post-analysis using national linked data registries with complete population coverage. The population consisted of patients admitted to all adult general ICUs during 2005 and surviving to hospital discharge, identified from the Scottish Intensive Care Society Audit Group registry, matched (1:1) with similar hospital control subjects. Five-year outcomes included mortality and hospital resource use. Confounder adjustment was based on multivariable regression and pre/post within-individual analyses.Measurements and Main Results: Of 7,656 ICU patients, 5,259 survived to hospital discharge (5,215 [99.2%] matched to hospital control subjects). Factors present before ICU admission (comorbidities/pre-ICU hospitalizations) were stronger predictors of hospital resource use than acute illness factors. In the 5 years after the initial hospital discharge, compared with hospital control subjects, the ICU cohort had higher mortality (32.3% vs. 22.7%; hazard ratio, 1.33; 95% confidence interval, 1.22–1.46; P < 0.001), used more hospital resources (mean hospital admission rate, 4.8 vs. 3.3/person/5 yr), and had 51% higher mean 5-year hospital costs ($25,608 vs. $16,913/patient). Increased resource use persisted after confounder adjustment (P < 0.001) and using pre/post-analyses (P < 0.001). Excess resource use and mortality were greatest for younger patients without significant comorbidity.Conclusions: This complete, national study demonstrates that ICU survivorship is associated with higher 5-year mortality and hospital resource use than hospital control subjects, representing a substantial burden on individuals, caregivers, and society.
A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors
Authors: F. G. De Braud, V. Gregorc, T. M. De Pas, G. Citterio, R. Scalamogna, S. Boselli, M. Giovannini, F. Caligaris- Cappio, A. Lambiase, C. Bordignon
Journal: Journal of Clinical Oncology (2008)

14647 Background: NGR-hTNF is a VTA exploiting a tumor-homing peptide (NGR) that selectively binds to aminopeptidase N/CD13 highly expressed on tumour blood vessels. NGR-hTNF combines activity on tumour vascular permeability and direct anticancer activity. Consistently, preclinical data indicate significant synergy between low-dose NGR-hTNF and cisplatin. Methods: Pts with solid tumors refractory to standard treatments, were treated with extremely low doses (20–200 fold lower than MTD) of NGR-hTNF given with a doubling-dose scheme (0.2–0.4–0.8–1.6 μg/m2) as 1-hour (h) intravenous infusion, in combination with cisplatin 80 mg/m2, both given every 3 weeks. A standard 3+3 escalation/de-escalation design was followed. Blood samples for PK and soluble TNF receptors analysis were collected just prior to and 9 time points up to 6 h after the first 3 cycles. Definition of DLT: any severe (G3–4) toxicity clearly related to NGR-hTNF. Results: 13 pts (10M/3F; median age: 58 [range: 47–73]; ECOG PS 0/1: 40%/60%) were enrolled. Tumour types were: mesothelioma (MPM, 3 pts), colorectal (3), lung (3), sarcoma (2), and melanoma (2). Median number of prior regimens was 2.5 (range: 1–6), with 78% of pts pretreated with a platinum-based regimen. Preliminary data showed no PK interaction and both NGR-hTNF Cmax and AUC increased in a dose-proportional manner. The combination was safe without an apparent exacerbation of platinum- associated toxicity profile. No DLTs were registered at dose levels (DL) 0.2 μg/m2 (n=4) and 0.4 μg/m2 (n=3). At DL 0.8 μg/m2 (n=3), a 65-year-old pt with MPM and lung metastases had a transient acute infusion reaction (G3 dyspnoea and hypoxia) not surely related to the dose. Nevertheless, this cohort was expanded to 6 pts for safety reason, with no DLTs registered. Conclusions: The combination of NGR-hTNF given at low doses in association with cisplatin 80 mg/m2 shows a manageable toxicity profile and will be further explored. Updated results will be presented at the meeting. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Molmed
Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement. clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M. D. Anderson Cancer Center.
Authors: G. F. Perini, J. E. Romaguera, M. A. Rodriguez, B. Pro, A. Younes, N. H. Fowler, F. B. Hagemeister, F. Samaniego, L. W. Kwak, L. Fayad
Journal: Journal of Clinical Oncology (2010)

8072 Background: DLBCL with BM involvement is an uncommon condition, and it is suspected to be a more aggressive condition with worse outcome and increased risk for CNS. There is controversy about the best modality of treatment, and it is unclear if CNS prophylaxis should be performed in every patient. Methods: We examined a database of new patients seen at M. D. Anderson Cancer Center from 1998 to 2008. We found patients who had DLBCL and LBCL in the bone marrow (140 patients with discordant histology or HIV positive serology was excluded). Patient characteristics included 51% male, 73% elevated LDH, and 53% older than 60 years. IPI distribution included 4% low-risk, 16.5% IL, 37% IH, 40% high-risk (2% N/A). All patients received rituximab CHOP-like therapy, and 52% received intrathecal prophylaxis. Results: With a median follow-up of 3.5 years for living patients, 45 of patients have developed relapse, with a median time to progression of 3.1 years. The 5-year overall survival rate was 51%; survival was associated with IPI (p=0.02), with 46% of the patients with high-risk dying of their disease. There were 10 (9%) CNS relapses, 5 in the prophylaxis and 5 in the non-prophylaxis group. All CNS relapses occurred in patients with elevated serum LDH at diagnosis, and in those with high- intermediate (50%) and high (50%) scores. Risk IPI scores nine of 10 patients with CNS relapse died of their disease. There were no differences between the CNS relapse rates for high-risk patients whether they received CNS prophylaxis (10% CNS relapse) or not (16% CNS relapse, p=0.4). Conclusions: In our patients, DLBCL with BM involvement commonly presented with high-risk features, CNS relapses occurred mostly in patients with HI and H-IPI scores and elevated LDH. The role of CNS prophylaxis in prevention of relapse remains unclear and new options for prevention of CNS relapse should be considered. No significant financial relationships to disclose.
Elevated dTTPase Activities in Sera of Patients With Advanced Cancer&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn3"&gt;3&lt;/xref&gt;
Authors: N Dahlmann
Journal: JNCI Journal of the National Cancer Institute (1982)

Journal Article Elevated dTTPase Activities in Sera of Patients With Advanced Cancer Get access Nicolaus Dahlmann, M.D. Nicolaus Dahlmann, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 69, Issue 3, September 1982, Pages 569–572, https://doi.org/10.1093/jnci/69.3.569 Published: 01 September 1982 Article history Received: 31 August 1981 Revision received: 03 March 1982 Accepted: 02 April 1982 Published: 01 September 1982
Cytogenetic studies in 77 patients with chronic lymphocytic leukemia: correlations with clinical, immunologic, and phenotypic data.
Authors: T Han, N Sadamori, H Ozer, R Gajera, G A Gomez, E S Henderson, A Bhargava, J Fitzpatrick, J Minowada, M L Bloom
Journal: Journal of Clinical Oncology (1984)

Cytogenetic analyses by G-banding and/or Q-banding techniques of polyclonal B cell mitogen-stimulated peripheral blood lymphocytes in 77 patients with chronic lymphocytic leukemia were carried out in the present study. Adequate metaphases were obtained in 65 patients (84%). Of 29 patients with abnormal karyotypes, ten (34%) had trisomy 12 as the sole abnormality, eight (28%) had trisomy 12 in combination with other karyotypic changes, and the remaining 11 had various karyotypic changes other than trisomy 12. There was a significant relationship between the abnormal karyotype and disease status, clinical stage, lymphocyte count, bone marrow infiltration pattern, monoclonal IgM gammopathy, and urinary monoclonal-free light chain status. Six of seven patients (87%) with trisomy 12 only had stage 0-11 disease, whereas all eight patients with trisomy 12 with other changes had stage III or IV disease (P less than .02). However, of nine patients with other karyotypic changes without trisomy 12, five had stage 0-II and four had stage III or IV disease. These observations suggest that trisomy 12 may be the primary or the earliest karyotypic change in a majority of aneuploid patients with chronic lymphocytic leukemia, and that other karyotypic changes in addition to trisomy 12 may develop as a result of clonal evolution, dedifferentiation, or therapy. Of nine patients in whom autopsy studies were carried out, four were found to have diffuse histiocytic lymphoma or Richter's syndrome (three with trisomy 12 in combination with other chromosome changes and one with normal karyotype). Our findings clearly demonstrate that cytogenetic study may be of value in the clinical and prognostic evaluation of patients with chronic lymphocytic leukemia.
Abstract P131: The Effects of Weight Loss on Liver Function in Obese Hypertensive Patients
Authors: Kazuko Masuo, Hiromi Rakugi, Toshio Ogihara, Gavin W Lambert
Journal: Circulation (2012)

Objective: Insulin resistance and visceral adiposity are predisposing factors for fatty liver disease. This study was undertaken to evaluate the weight loss effects on liver function (ALT, AST, GGT). Methods: 90 overweight/obese, mild hypertensive men without medications or liver dysfunction were randomized into the 3 weight loss (WL) regimens over 24 weeks. WL was achieved with i) a mild calorie restricted diet alone (D alone; 1800kcal/day, 55% carbohydrate, 30% protein, 15% fat), ii) mild exercise alone (EX alone; 1-hr walking), or iii) a combination with a mild calorie restricted diet + exercise (D+EX) over 24 weeks. BMI, waist/hip ratio (W/H), total body fat-mass, blood pressure (BP), plasma norepinephrine (NE), fasting insulin, glucose, HOMA-IR, total cholesterol (Tch), triglyceride (TG), and liver function (ALT, AST, GGT) were measured every 4 weeks over 24 weeks with WL. Results: At entry period, BMI, fat-mass, W/H, BP levels, plasma NE, HOMA-IR, Tch, TG, ALT, AST, and GGT were similar between the 3 groups. At 24 weeks, the D+EX group had significantly higher prevalence of normalizations of BMI and BP levels (53.3%, 56.7%, respectively) compared to the D alone (13.3%, 23.3%, 30.0%) or EX alone (26.6%, 23.3%). In the D alone group, significant decreases in plasma NE and TG was observed at 2 weeks followed by significant reductions in Tch, body weight, fat mass, and HOMA at 8 weeks. Significant reductions in W/H, BP and GGT were also observed at 8 weeks, and ALT and AST decreased gradually but significantly at 12 weeks. On the other hand, in the EX alone group, significant fat loss and significant reduction in W/H, HOMA-IR and GGT were observed at 4 weeks. Body weight and plasma NE decreased significantly at 8 weeks, and significant BP reduction and decreases in TG and Tch were occurred at 12 weeks followed by decreases in ALT and AST at 16 weeks. Reductions in GGT were similar between the D alone and D+EX groups, but the groups including D had greater reduction in GGT, ALT and AST compared to the EX alone group. In the combination group (D+EX group), every improvement was observed earlier and stronger. Significant suppression on plasma NE and TG was at 2 weeks, decreases in HOMA, Tch, weight, fat-mass, W/H, systolic BP and GGT were at 4 weeks, and diastolic BP, ALT, and AST were at 8 weeks. In all subjects, reductions in HOMA-IR preceded to decreases in liver function parameters (GGT, ALT, and AST), and reductions in GGT was followed by decreases in ALT or AST. In multiple regression analyses, at both period of entry and 24-week, HOMA-IR was a significant determinant for GGT, TG and Tch. At entry and 24-week periods, Tch, but not TG, was a significant determinant for GGT, ALT, and AST. Conclusions: Improvement of insulin resistance associated with WL may play an important role of improvement of liver function during lifestyle modifications. WL is an effective treatment for fatty liver disease associated with obesity.
Injury risk in runners using standard or motion control shoes: a randomised controlled trial with participant and assessor blinding
Authors: Laurent Malisoux, Nicolas Chambon, Nicolas Delattre, Nils Gueguen, Axel Urhausen, Daniel Theisen
Journal: British Journal of Sports Medicine (2016)

Background/aim This randomised controlled trial investigated if the usage of running shoes with a motion control system modifies injury risk in regular leisure-time runners compared to standard shoes, and if this influence depends on foot morphology. Methods Recreational runners (n=372) were given either the motion control or the standard version of a regular running shoe model and were followed up for 6 months regarding running activity and injury. Foot morphology was analysed using the Foot Posture Index method. Cox regression analyses were used to compare injury risk between the two groups, based on HRs and their 95% CIs, controlling for potential confounders. Stratified analyses were conducted to evaluate the effect of motion control system in runners with supinated, neutral and pronated feet. Results The overall injury risk was lower among the participants who had received motion control shoes (HR=0.55; 95% CI 0.36 to 0.85) compared to those receiving standard shoes. This positive effect was only observed in the stratum of runners with pronated feet (n=94; HR=0.34; 95% CI 0.13 to 0.84); there was no difference in runners with neutral (n=218; HR=0.78; 95% CI 0.44 to 1.37) or supinated feet (n=60; HR=0.59; 95% CI 0.20 to 1.73). Runners with pronated feet using standard shoes had a higher injury risk compared to those with neutral feet (HR=1.80; 95% CI 1.01 to 3.22). Conclusions The overall injury risk was lower in participants who had received motion control shoes. Based on secondary analysis, those with pronated feet may benefit most from this shoe type.
How durable are behavioral changes? Results from FRESH START: A randomized controlled trial to improve diet and exercise behaviors in breast and prostate cancer survivors
Authors: W. Demark-Wahnefried, E. C. Clipp, I. M. Lipkus, D. Lobach, B. Peterson, D. C. Snyder, R. Sloane, W. E. Kraus
Journal: Journal of Clinical Oncology (2007)

9019 Background: A healthy diet and regular exercise may improve the health, well-being and ultimate survival of cancer survivors. Last year, results of the FRESH START trial (n=543) were presented at ASCO; significant improvements in diet and exercise behaviors of breast and prostate cancer survivors were observed with two 10-month mailed print interventions - one that was sequentially- tailored and another using non-tailored print materials in the public domain (attention control). While both arms achieved significant improvements, those receiving the tailored intervention reported significantly greater changes (all p-values &lt;.05). The durability of these changes, however, is not known. Methods: At 2-year follow-up, and after a 12-month wash-out, telephone surveys that were conducted at baseline and post-intervention (Diet History Questionnaire and 7-Day Physical Activity Recall) were repeated. Results: Ordinary Least Square analysis suggest that changes from baseline largely remain significant at 2-year follow-up for both interventions (see table ). Moreover, significant differences between arms are observed for dietary fat restriction and the practice of more lifestyle behaviors at goal level [i.e., consumption of ≥ 5 servings/day of fruits &amp; vegetables (F&amp;V), &lt; 30% kcal from fat, and &gt;150 min/week of exercise], with the tailored intervention arm achieving levels superior to those achieved in the attention control arm. Conclusions: Tailored and untailored interventions delivered over a 10-month period to cancer survivors exert durable effects on several lifestyle behaviors. However, the effects of the tailored intervention were initially more powerful and largely sustained over time (especially, with regard dietary fat restriction). No significant financial relationships to disclose. [Table: see text]
Abstract 17147: Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease and No Clinical Evidence of Heart Failure: A Meta-Analysis of Randomized Controlled Trials
Authors: Vu Hoang, Daniel Addison, Yochai Birnbaum, Mahboob Alam
Journal: Circulation (2013)

Data from randomized controlled trials of angiotensin-converting enzyme inhibitors (ACEi) in patients with coronary artery disease (CAD) but no clinical evidence of heart failure are inconclusive. ...